|GDC-0853|CsnPharm

CAS No.: 1434048-34-6

Fenebrutinib Catalog No. CSN19159

Synonyms: GDC-0853;RG7845

GDC-0853 is a potent and orally BTK inhibitor.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述GDC-0853 is a potent and orally BTK inhibitor.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03137069	Urticaria	Phase 2	Recruiting	January 23, 2019	-
NCT02833350	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT03174041	Healthy Participants	Phase 1	Completed	-	United States, Florida ... more >> Covance Research Unit - Daytona Daytona Beach, Florida, United States, 32117 United States, Indiana Covance Clinical Research Unit Inc.; Covance Gfi Research Evansville, Indiana, United States, 47710 United States, Wisconsin Covance Clinical Research Unit, Inc Madison, Wisconsin, United States, 53704 Collapse <<

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.5042 mL
- 7.5211 mL
- 15.0421 mL
- 5 mM
- 0.3008 mL
- 1.5042 mL
- 3.0084 mL
- 10 mM
- 0.1504 mL
- 0.7521 mL
- 1.5042 mL

技术信息

CAS号

1434048-34-6

储存条件

粉末: Keep in dark place,Sealed in dry,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C37H44N8O4

运输

蓝冰

分子量

664.80

别名

GDC-0853;RG7845

溶解度

DMSO	8.0 mg/mL (12.0 mM)
Water	Insoluble
Ethanol	Insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03137069	Urticaria	Phase 2	Recruiting	January 23, 2019	-
NCT02833350	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT03174041	Healthy Participants	Phase 1	Completed	-	United States, Florida ... more >> Covance Research Unit - Daytona Daytona Beach, Florida, United States, 32117 United States, Indiana Covance Clinical Research Unit Inc.; Covance Gfi Research Evansville, Indiana, United States, 47710 United States, Wisconsin Covance Clinical Research Unit, Inc Madison, Wisconsin, United States, 53704 Collapse <<
NCT02699710	Healthy Volunteer	Phase 1	Completed	-	United Kingdom ... more >> Quotient Clinical Ltd, Clinical Research Unit Nottingham, United Kingdom, NG11 6JS Collapse <<
NCT03290703	Healthy Volunteers	Phase 1	Completed	-	United Kingdom ... more >> Quotient Clinical Ltd, Clinical Research Unit Nottingham, United Kingdom, NG11 6JS Collapse <<
NCT03693625	Urticaria	Phase 2	Recruiting	September 26, 2020	-
NCT03188783	Healthy Volunteer	Phase 1	Completed	-	United States, California ... more >> West Coast Clinical Trials Cypress, California, United States, 90630 Collapse <<
NCT02983227	RheumatoId Arthritis	Phase 2	Active, not recruiting	September 12, 2019	-
NCT02908100	Systemic Lupus Erythematosus	Phase 2	Active, not recruiting	June 29, 2019	-
NCT03407482	Lupus Erythematosus, Systemic	Phase 2	Recruiting	April 9, 2020	-
NCT01991184	Lymphocytic Leukemia, Chronic,... more >> Diffuse Large B-Cell Lymphoma Collapse <<	Phase 1	Active, not recruiting	March 1, 2019	United States, California ... more >> Stanford Cancer Center Stanford, California, United States, 94305-5820 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio The Ohio State University Wexner Medical Center Columbus, Ohio, United States, 43212 United States, Oregon Willamette Valley Cancer Ctr - 520 Country Club Eugene, Oregon, United States, 97401-8122 Oregon Health Sciences Uni Portland, Oregon, United States, 97239 United States, Tennessee Sarah Cannon Cancer Center - Tennessee Oncology, Pllc Nashville, Tennessee, United States, 37203 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Australia, Queensland Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology Woolloongabba, Queensland, Australia, 4102 Australia, Victoria Peter MacCallum Cancer Centre; Department of Haematology Melbourne, Victoria, Australia, 3002 Australia, Western Australia Linear Clinical Research Limited Nedlands, Western Australia, Australia, 6009 Collapse <<

Fenebrutinib Catalog No. CSN19159

靶点选择性

请登录您的专属账户

确认信息